

CELL THERAPEUTICS INC  
Form 8-K  
October 20, 2003

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2003

## CELL THERAPEUTICS, INC.

---

(Exact name of Registrant as specified in its charter)

Washington

(State or other jurisdiction of  
incorporation or organization)

0-28386

(Commission File Number)

91-1533912

(I.R.S. Employer  
Identification Number)

**501 Elliott Avenue West, Suite 400**

**Seattle, WA 98119**

---

**(Address of principal executive offices) (Zip Code)**

**(206) 282-7100**

---

**(Registrant's telephone number, including area code)**

**Not Applicable**

---

**(Former name or former address, if changed since last report.)**

---

**Item 5. Other Events.**

On October 20, 2003, Cell Therapeutics, Inc. issued a press release announcing that it had implemented a study amendment in its STELLAR 4 trial. The full text of the press release is set forth in Exhibit 99.1 hereto and is incorporated herein by reference.

**Item 7. Financial Statements and Exhibits.**

(c) Exhibits.

<u>Exhibit</u>	<u>Description</u>
99.1	Press release of Cell Therapeutics, Inc. issued on October 20, 2003.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELL THERAPEUTICS, INC.

a Washington corporation

October 20, 2003

By:

/s/ James A. Bianco, M.D.

---

James A. Bianco, M.D.

*President and Chief Executive Officer*

**Index to Exhibits**

<b>Exhibit</b>	<b>Description</b>
99.1	Press release of Cell Therapeutics, Inc. issued on October 20, 2003.